{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T20:36:04Z","timestamp":1774125364808,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1038\/ncprheum0336","type":"journal-article","created":{"date-parts":[[2006,10,31]],"date-time":"2006-10-31T10:02:07Z","timestamp":1162288927000},"page":"602-610","source":"Crossref","is-referenced-by-count":218,"title":["Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor"],"prefix":"10.1038","volume":"2","author":[{"given":"Kevin L","family":"Winthrop","sequence":"first","affiliation":[]}],"member":"297","reference":[{"issue":"Suppl 4","key":"BFncprheum0336_CR1","doi-asserted-by":"crossref","first-page":"iv2","DOI":"10.1136\/ard.2005.044941","volume":"64","author":"DE Furst","year":"2005","unstructured":"Furst DE et al. (2005) Updated consensus statement on biological agents, specifically tumour necrosis factor-\u03b1 (TNF-\u03b1) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 64 (Suppl 4): iv2\u2013iv14","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0336_CR2","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1002\/art.11301","volume":"48","author":"T Ellerin","year":"2003","unstructured":"Ellerin T et al. (2003) Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 48: 3013\u20133022","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0336_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/01.md.0000180044.19285.9a","volume":"84","author":"NF Crum","year":"2005","unstructured":"Crum NF et al. (2005) Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 84: 291\u2013302","journal-title":"Medicine (Baltimore)"},{"key":"BFncprheum0336_CR4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"RS Wallis","year":"2004","unstructured":"Wallis RS et al. (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38: 1261\u20131265","journal-title":"Clin Infect Dis"},{"key":"BFncprheum0336_CR5","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1086\/424455","volume":"39","author":"RS Wallis","year":"2004","unstructured":"Wallis RS et al. (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. [Erratum] Clin Infect Dis 39: 1254\u20131255","journal-title":"Clin Infect Dis"},{"key":"BFncprheum0336_CR6","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor-\u03b1 neutralizing agent. N Engl J Med 345: 1098\u20131104","journal-title":"N Engl J Med"},{"key":"BFncprheum0336_CR7","unstructured":"Centers for Disease Control and Prevention (CDC) (2004) Tuberculosis associated with blocking agents against tumor necrosis factor-alpha\u2014California, 2002\u20132003. MMWR Morb Mortal Wkly Rep 53: 683\u2013686"},{"key":"BFncprheum0336_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1086\/421494","volume":"39","author":"AK Mohan","year":"2004","unstructured":"Mohan AK et al. (2004) Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 39: 295\u2013299","journal-title":"Clin Infect Dis"},{"key":"BFncprheum0336_CR9","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/art.21382","volume":"52","author":"KL Winthrop","year":"2005","unstructured":"Winthrop KL et al. (2005) Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum 52: 2968\u20132974","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0336_CR10","doi-asserted-by":"crossref","unstructured":"British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60: 800\u2013805","DOI":"10.1136\/thx.2005.046797"},{"key":"BFncprheum0336_CR11","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/rheumatology\/kei103","volume":"44","author":"J Ledingham","year":"2005","unstructured":"Ledingham J et al. (2005) British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-\u03b1 treatments. Rheumatology (Oxford) 44: 1205\u20131206","journal-title":"Rheumatology (Oxford)"},{"key":"BFncprheum0336_CR12","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1053\/gast.2000.18160","volume":"119","author":"SR Papadakis KA and Targan","year":"2000","unstructured":"Papadakis KA and Targan SR (2000) Tumor necrosis factor: biology and therapeutic implications. Gastroenterology 119: 1148\u20131157","journal-title":"Gastroenterology"},{"issue":"Suppl 3","key":"BFncprheum0336_CR13","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1086\/429998","volume":"41","author":"S Ehlers","year":"2005","unstructured":"Ehlers S (2005) Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 41 (Suppl 3): S199\u2013S203","journal-title":"Clin Infect Dis"},{"key":"BFncprheum0336_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.cdd.4401189","volume":"10","author":"H Wajant","year":"2003","unstructured":"Wajant H et al. (2003) Tumor necrosis factor signaling. Cell Death Differ 10: 45\u201365","journal-title":"Cell Death Differ"},{"key":"BFncprheum0336_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","volume":"2","author":"JL Flynn","year":"1995","unstructured":"Flynn JL et al. (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2: 561\u2013572","journal-title":"Immunity"},{"issue":"Suppl 3","key":"BFncprheum0336_CR16","doi-asserted-by":"publisher","first-page":"S189","DOI":"10.1086\/429994","volume":"41","author":"HM Algood","year":"2005","unstructured":"Algood HM et al. (2005) Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 41 (Suppl 3): S189\u2013S193","journal-title":"Clin Infect Dis"},{"key":"BFncprheum0336_CR17","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","volume":"168","author":"RR Roach","year":"2002","unstructured":"Roach RR et al. (2002) TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168: 4620\u20134627","journal-title":"J Immunol"},{"key":"BFncprheum0336_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","volume":"56","author":"V Kindler","year":"1989","unstructured":"Kindler V et al. (1989) The inducing role of tumor necrosis factor in the development of bactericidal gramulomas during BCG infection. Cell 56: 731\u2013740","journal-title":"Cell"},{"key":"BFncprheum0336_CR19","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1128\/IAI.69.3.1847-1855.2001","volume":"69","author":"VP Mohan","year":"2001","unstructured":"Mohan VP et al. (2001) Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting patholology. Infect Immun 69: 1847\u20131855","journal-title":"Infect Immun"},{"key":"BFncprheum0336_CR20","doi-asserted-by":"publisher","first-page":"6728","DOI":"10.4049\/jimmunol.166.11.6728","volume":"166","author":"LG Bekker","year":"2001","unstructured":"Bekker LG et al. (2001) TNF-\u03b1 controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 166: 6728\u20136734","journal-title":"J Immunol"},{"key":"BFncprheum0336_CR21","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1128\/IAI.63.12.4862-4867.1995","volume":"63","author":"JS Silva","year":"1995","unstructured":"Silva JS et al. (1995) Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infect Immun 63: 4862\u20134867","journal-title":"Infect Immun"},{"key":"BFncprheum0336_CR22","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.4049\/jimmunol.161.5.2383","volume":"161","author":"S Juttner","year":"1998","unstructured":"Juttner S et al. (1998) Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha. J Immunol 161: 2383\u20132390","journal-title":"J Immunol"},{"key":"BFncprheum0336_CR23","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/364798a0","volume":"364","author":"J Rothe","year":"1993","unstructured":"Rothe J et al. (1993) Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364: 798\u2013802","journal-title":"Nature"},{"issue":"Suppl 3","key":"BFncprheum0336_CR24","doi-asserted-by":"publisher","first-page":"S204","DOI":"10.1086\/429999","volume":"41","author":"GS Deepe Jr","year":"2005","unstructured":"Deepe GS Jr (2005) Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity. Clin Infect Dis 41 (Suppl 3): S204\u2013S207","journal-title":"Clin Infect Dis"},{"key":"BFncprheum0336_CR25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1128\/IAI.67.2.595-601.1999","volume":"67","author":"DP O'Brien","year":"1999","unstructured":"O'Brien DP et al. (1999) Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. Infect Immun 67: 595\u2013601","journal-title":"Infect Immun"},{"issue":"Suppl 3","key":"BFncprheum0336_CR26","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1086\/430126","volume":"41","author":"TA Moore","year":"2005","unstructured":"Moore TA et al. (2005) Defective innate antibacterial host responses during murine Klebsiella pneumoniae bacteremia: tumor necrosis factor (TNF) receptor 1 deficiency versus therapy with anti-TNF-alpha. Clin Infect Dis 41 (Suppl 3): S213\u2013S217","journal-title":"Clin Infect Dis"},{"key":"BFncprheum0336_CR27","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1124\/jpet.301.2.418","volume":"301","author":"B Scallon","year":"2002","unstructured":"Scallon B et al. (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301: 418\u2013426","journal-title":"J Pharmacol Exp Ther"},{"key":"BFncprheum0336_CR28","first-page":"1153","volume":"168","author":"R Long","year":"2003","unstructured":"Long R and Gardam MA (2003) Tumour necrosis factor-\u03b1 inhibitors and the reactivation of latent tuberculosis infection. CMAJ 168: 1153\u20131156","journal-title":"CMAJ"},{"key":"BFncprheum0336_CR29","unstructured":"Canadian Pharmacists Association (2002) Remicade (infliximab) Schering Canada [product monograph]. In Compendium of pharmaceuticals and specialties, 1443. Toronto: Webcom Ltd"},{"key":"BFncprheum0336_CR30","unstructured":"Canadian Pharmacists Association (2002) Enbrel (etanercept) Wyeth-Ayerst [product monograph]. In Compendium of pharmaceuticals and specialties, 569. Toronto: Webcom Ltd"},{"key":"BFncprheum0336_CR31","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","volume":"124","author":"JM Van den Grande","year":"2003","unstructured":"Van den Grande JM et al. (2003) Infliximab but not etancercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124: 1774\u20131785","journal-title":"Gastroenterology"},{"key":"BFncprheum0336_CR32","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1365-2036.2005.02309.x","volume":"21","author":"C Shen","year":"2005","unstructured":"Shen C et al. (2005) Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21: 251\u2013258","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncprheum0336_CR33","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1053\/gast.2001.28702","volume":"121","author":"A Lugering","year":"2001","unstructured":"Lugering A et al. (2001) Infliximab induces apotosis in monocytes from patient with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121: 1145\u20131157","journal-title":"Gastroenterology"},{"key":"BFncprheum0336_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S0016-5085(99)70224-6","volume":"116","author":"FJ Baert","year":"1999","unstructured":"Baert FJ et al. (1999) Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116: 22\u201328","journal-title":"Gastroenterology"},{"key":"BFncprheum0336_CR35","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1053\/gast.2001.28674","volume":"121","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ et al. (2001) Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088\u20131094","journal-title":"Gastroenterology"},{"key":"BFncprheum0336_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/01.bor.0000200369.24793.f5","volume":"18","author":"B Hellmich","year":"2006","unstructured":"Hellmich B et al. (2006) Advances in the therapy of Wegener's granulomatosis. Curr Opin Rheumatol 18: 25\u201332","journal-title":"Curr Opin Rheumatol"},{"key":"BFncprheum0336_CR37","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1378\/chest.127.3.1064","volume":"127","author":"JD Doty","year":"2005","unstructured":"Doty JD et al. (2005) Treatment of sarcoidosis with infliximab. Chest 127: 1064\u20131071","journal-title":"Chest"},{"key":"BFncprheum0336_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/art.20764","volume":"52","author":"AI Catrina","year":"2005","unstructured":"Catrina AI et al. (2005) Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52: 61\u201372","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"BFncprheum0336_CR39","first-page":"S274","volume":"52","author":"RS Wallis","year":"2005","unstructured":"Wallis RS et al. (2005) Differential effects of tumor necrosis factor blockers on mycobacterial immunity in vitro [abstract]. Arthritis Rheum 52 (Suppl): S274","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0336_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1043-4666(03)00201-1","volume":"23","author":"J Agnholt","year":"2003","unstructured":"Agnholt J et al. (2003) The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 23: 76\u201385","journal-title":"Cytokine"},{"key":"BFncprheum0336_CR41","unstructured":"World Health Organization (online March 2006) Fact sheet no. 104: tuberculosis [ http:\/\/www.who.int\/mediacentre\/factsheets\/fs104\/en\/ ] (Accessed 15 September 2006)"},{"key":"BFncprheum0336_CR42","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1473-3099(03)00741-2","volume":"3","author":"JM Tufariello","year":"2003","unstructured":"Tufariello JM et al. (2003) Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 3: 578\u2013590","journal-title":"Lancet Infect Dis"},{"key":"BFncprheum0336_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","volume":"3","author":"MA Gardam","year":"2003","unstructured":"Gardam MA et al. (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3: 148\u2013155","journal-title":"Lancet Infect Dis"},{"key":"BFncprheum0336_CR44","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor-\u03b1 neutralizing agent. N Engl J Med 345: 1098\u20131104","journal-title":"N Engl J Med"},{"key":"BFncprheum0336_CR45","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1164\/ajrccm\/141.2.347","volume":"141","author":"HL Rieder","year":"1990","unstructured":"Rieder HL et al. (1990) Extrapulmonary tuberculosis in the United States. Am Rev Respir Dis 141: 347\u2013351","journal-title":"Am Rev Respir Dis"},{"key":"BFncprheum0336_CR46","unstructured":"FDA briefing document (online 4 March 2003) Update on the TNF-\u03b1 blocking agents. [ http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3930B1_01_B-TNF.Briefing.pdf .] (accessed 15 September 2006)"},{"issue":"Suppl III","key":"BFncprheum0336_CR47","first-page":"86","volume":"64","author":"JL Perez","year":"2005","unstructured":"Perez JL et al. (2005) Impact of screening for latent TB prior to initiation anti-TNF therapy in North America and Europe. Ann Rheum Dis 64 (Suppl III): 86","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"BFncprheum0336_CR48","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1086\/429996","volume":"41","author":"RS Wallis","year":"2005","unstructured":"Wallis RS et al. (2005) Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41 (Suppl 3): S194\u2013S198","journal-title":"Clin Infect Dis"},{"key":"BFncprheum0336_CR49","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1002\/art.21386","volume":"52","author":"J Listing","year":"2005","unstructured":"Listing J et al. (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52: 3403\u20133412","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0336_CR50","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1086\/426434","volume":"40","author":"F Tissot","year":"2005","unstructured":"Tissot F et al. (2005) Influence of bacillus Calmette\u2013Gu\u00e9rin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 40: 211\u2013217","journal-title":"Clin Infect Dis"},{"key":"BFncprheum0336_CR51","unstructured":"Centers for Disease Control and Prevention (1997) Anergy skin testing and tuberculosis preventive therapy for HIV-infected persons: revised recommendations. MMWR Recomm Rep 46 (RR-15): 1\u201310"},{"key":"BFncprheum0336_CR52","unstructured":"American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161 (Pt 2): S221\u2013S247"},{"key":"BFncprheum0336_CR53","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S1473-3099(04)01206-X","volume":"4","author":"M Pai","year":"2004","unstructured":"Pai M et al. (2004) Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 4: 761\u2013776","journal-title":"Lancet Infect Dis"},{"key":"BFncprheum0336_CR54","first-page":"49","volume":"54 (RR-15)","author":"GH Mazurek","year":"2005","unstructured":"Mazurek GH et al. (2005) Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 54 (RR-15): 49\u201355","journal-title":"MMWR Recomm Rep"},{"key":"BFncprheum0336_CR55","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1086\/505877","volume":"194","author":"M Zignol","year":"2006","unstructured":"Zignol M et al. (2006) Global incidence of multidrug-resistant tuberculosis. J Infect Dis 194: 479\u2013485","journal-title":"J Infect Dis"},{"key":"BFncprheum0336_CR56","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/art.20009","volume":"50","author":"F Wolfe","year":"2004","unstructured":"Wolfe F et al. (2004) Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50: 372\u2013379","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0336_CR57","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/art.21043","volume":"52","author":"L Carmona","year":"2005","unstructured":"Carmona L et al. (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52: 1766\u20131772","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0336_CR58","first-page":"1","volume":"51 (RR-8)","author":"JE Kaplan","year":"2002","unstructured":"Kaplan JE et al. (2002) Infectious Disease Society of America. Guidelines for preventing opportunisitic infections among HIV-infected persons\u20142002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 51 (RR-8): 1\u201352","journal-title":"MMWR Recomm Rep"},{"key":"BFncprheum0336_CR59","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1034\/j.1399-3062.2003.00005.x","volume":"5","author":"JE Blair","year":"2003","unstructured":"Blair JE et al. (2003) Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area. Transpl Infect Dis 5: 3\u20138","journal-title":"Transpl Infect Dis"},{"key":"BFncprheum0336_CR60","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/art.20454","volume":"50","author":"L Bergstrom","year":"2004","unstructured":"Bergstrom L et al. (2004) Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 50: 1959\u20131966","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0336_CR61","unstructured":"US Food and Drug Administration. MedWatch: the FDA safety information and adverse event reporting program [ http:\/\/www.fda.gov\/medwatch ] (accessed 15 September 2006)"},{"key":"BFncprheum0336_CR62","unstructured":"Centers for Disease Control and Prevention (CDC) and American Thoracic Society (2003) Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection\u2014United States, 2003. MMWR Morb Mortal Wkly Rep 52: 735\u2013739"},{"key":"BFncprheum0336_CR63","unstructured":"American Thoracic Society (CDC) and Infectious Diseases Society of America (2003) Treatment of tuberculosis. MMWR Recomm Rep 52 (RR-11): 1\u201377"}],"container-title":["Nature Clinical Practice Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0336","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncprheum0336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T18:56:01Z","timestamp":1736621761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncprheum0336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["BFncprheum0336"],"URL":"https:\/\/doi.org\/10.1038\/ncprheum0336","relation":{},"ISSN":["1745-8382","1745-8390"],"issn-type":[{"value":"1745-8382","type":"print"},{"value":"1745-8390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}